

Evaluation of possible salivary biomarkers for early detection of graft versus host disease in patients submitted to allogeneic hematopoietic stem cell transplantation

Táisa Domingues Bernardes Silva(PhD student)¹, Camila Brandão Lobo¹, Héilton Spíndola Antunes², Eliana Abdelhay¹, Renata Binato¹
¹Stem cell laboratory of the bone marrow transplant center – INCA / ²Clinical research – INCA


INTRODUCTION

Hematopoietic stem cell transplantation (HSCT)



- Indication** →
- Malignant and nonmalignant hematological diseases;
 - Myelodysplastic syndrome;
 - Immunodeficiencies;
 - Some solid tumors.
- Conditioning** →
- Chemotherapy and/or Radiotherapy
- Complications** →
- Infections;
 - Bleeding;
 - Toxicity;
 - Relapse;
 - Secondary malignancy;
 - **GVHD**

Is still the main and most serious complication after transplantation; it is the main cause of "non-relapse" mortality after HSCT.




Homeostasis in the oral cavity is maintained by a complex network of innate and adaptive immune proteins and normal oral flora.

OBJECTIVES

Identify proteins that can predict the risk of developing GVHD by evaluate the salivary protein expression of pre-allogeneic HSCT patients when comparing patients that developed or not GVHD posteriorly.

METHODOLOGY




PARTIAL RESULTS

GROUP 1

Patients	Gender	Age	Conditioning	Transplant (DD/MM/AAAA)	Related Donor	Source	Diagnoses	Sistemic GVHD	Oral GVHD
1001086	M	16	CY + TBI	22/09/2017	Yes	BM	ALL	Yes	No
1001087	M	26	CY + FLU + ATG	22/09/2017	No	PB	AML	Yes	No
1001088	M	29	FLU + TBI	28/09/2017	Yes	BM	ALL	Yes	Yes
1001089	M	26	CY + BU	05/07/2017	Yes	BM	AML	Yes	Yes
1001090	F	39	CY + BU	05/10/2017	Yes	BM	AML	Yes	No
1001091	F	50	BU + FLU	11/10/2017	Yes	BM	AML	Yes	Yes
1001092	F	58	BU + FLU + ATG	11/10/2017	No	BM	AML	No	No
1001093	M	20	FLU + TBI	20/10/2017	No	BM	AA	No	No
1001096	F	49	BU + CY	10/11/2017	Yes	BM	AML	No	No
1001097	F	13	BU + CY + ATG	09/11/2017	No	BM	AML	Yes	No
1001098	M	14	CY + FLU + TBI	23/11/2017	No	BM	ALL	No	No
1001099	F	60	BU + FLU	30/11/2017	Yes	BM	SAA/MDS	No	No
1001100	M	45	CY + FLU + TBI + PTCY	12/12/2017	Yes	PB	AA	No	No
1001102	M	15	CY + BU	06/12/2017	No	BM	ALL	Yes	Yes
1001103	F	56	BU + FLU	06/12/2017	Yes	BM	AML	No	No
1001107	F	27	FLU + CY + TBI + PTCY	20/12/2017	Yes	BM	SAA	No	No
1001109	F	60	CY + ATB + TBI	20/12/2017	No	BM	ALL	Yes	No
1001110	M	36	CY + ATG + TBI	24/01/2018	No	PB	ALL	No	No
1001111	F	50	CY + BU	26/01/2018	Yes	BM	ALL	Yes	No
1001112	M	11	FLU + TBI	08/02/2018	Yes	BM	ALL	Yes	No
1001113	F	67	BU + FLU	07/03/2018	Yes	BM	Mielofibrosis	Yes	No
1001114	M	43	FLU + TBI + PTCY	08/03/2018	Yes	BM	ALL	Yes	No
1001115	M	30	CY + TBI	15/03/2018	Yes	BM	ALL	-	-
1001116	M	44	FLU + CY + ATG	22/03/2018	No	PB	NLH	-	-
1001117	M	40	BU + FLU + CY	28/03/2018	Yes	BM	ALL	-	-
1001118	M	29	CY + TBI + ATG	28/03/2018	No	BM	ALL	Yes	No
1001119	F	35	CY + TBI	12/04/2018	Yes	BM	CML	Yes	Yes
1001121	M	10	CY + ATG + TBI	10/05/2018	No	BM	ALL	-	-
1001123	M	26	BU + FLU	23/05/2018	No	BM	CML	-	-

GROUP 2



PERSPECTIVES

The collection of saliva, in addition to being a non-invasive procedure and easy to perform, is an important way to identify a biomarker. Therefore, we hope, through protein analysis, we will be able to identify potential biomarkers in saliva that may predict the risk of developing GVHD.